Drug Profile

Lutetium-177 SN 201- Spago Nanomedical

Alternative Names: 177Lu-SN201; Tumorad

Latest Information Update: 26 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Spago NanoMedical
Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Cancer

Most Recent Events

24 Apr 2024 Pharmacodynamics data from preclinical study in Breast cancer released by Spago Nanomedical AB
30 Nov 2023 Phase-I/II clinical trials in Cancer (Late-stage disease, Inoperable/Unresectable, Refractory metastatic disease, Recurrent, Second-line therapy or greater) in Australia (IV) (NCT06184035)
24 Oct 2023 Spago Nanomedical files for extended patent protection for Tumorad and 177 Lu-SN 201 in EU, USA and Japan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com